by optimizenetz | Oct 6, 2015 | Medicine Cabinet
The Food and Drug Administration (FDA) has surprised healthcare professionals when it recently announced the approval of both insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg) 70/30. The FDA refused to approve Tresiba and...
by optimizenetz | Sep 15, 2015 | Medicine Cabinet
Metformin is recommended as initial therapy for type 2 diabetes and is used as monotherapy or in combination with other antidiabetic oral agents and insulin. It has been found to be an effective treatment for many patients, but it is also important to point some...
by optimizenetz | Sep 2, 2015 | Medicine Cabinet
A new study states Jardiance (Empaglifluzin, Eli Lilly and Boehringer Ingelheim) reduces the risk of heart attacks, strokes and other cardiovascular damage. Jardiance is a sodium glucose transport (SGLT-2 inhibitor) inhibitor, and is indicated as an adjunct to diet...
by optimizenetz | Aug 11, 2015 | Medicine Cabinet
Late last year, the American Diabetes Association (ADA) recommended the use of cholesterol-lowering medications (statins) in all patients with diabetes. ADA’s recommendation included moderate-intensity statins for people under age 40 with diabetes. Moderate-intensity...
by optimizenetz | Jul 24, 2015 | Medicine Cabinet
Poor adherence to medical treatment is widespread and well recognized. Poor adherence to medication therapy either because medication doses are forgotten or the patient experiences adverse effects and stops taking medication, may lead to poor health outcomes and...
by optimizenetz | Jul 17, 2015 | Medicine Cabinet
Recently, there was a discussion surrounding the connection between dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk for cardiovascular disease (CVD) or hospitalization for heart failure (HF). Such concerns could affect providers’ prescribing habits of...
